Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients

CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells

Henn, V., Slupsky, J. R., Gräfe, M., Anagnostopoulos, I., Förster, R., MÜLLER‐BERGHAUS, G., & Kroczek, R. A. (1998) · Nature · doi:10.1038/35393 · Cited by 2,082

Activation of human dendritic cells through CD40 cross-linking.

Caux, C., Massacrier, C., Vanbervliet, B., Dubois, B., van Kooten, C., Durand, I., & Banchereau, J. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.180.4.1263 · Cited by 1,317

Therapy of Lupus Nephritis

Austin, H. A., Klippel, J. H., Balow, J. E., LeRICHE, N. G. H., Steinberg, A. D., Plötz, P. H., & Decker, J. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603063141004 · Cited by 1,189

Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis

Chan, T. M., Li, F., Tang, C. S.-O., Wong, R. W. S., Fang, G. X., Ji, Y., Lau, C. S., Wong, A. K., Tong, M. K. L., Chan, K. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431604 · Cited by 949

CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates

Kirk, A. D., Harlan, D. M., Armstrong, N. N., Davis, T. A., Dong, Y., Gray, G. S., Hong, X., Thomas, D. W., Fechner, J. H., & Knechtle, S. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.16.8789 · Cited by 928

Soluble CD40 Ligand in Acute Coronary Syndromes

Heeschen, C., Dimmeler, S., Hamm, C. W., van den Brand, M. J., Boersma, E. H., Zeiher, A. M., & Simoons, M. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022600 · Cited by 827

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

Boumpas, D. T., Austin, H. A., Balow, J. E., Vaughan, E. M., Yarboro, C. H., Klippel, J. H., & Steinberg, A. D. (1992) · The Lancet · doi:10.1016/0140-6736(92)92292-n · Cited by 820

Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for CD40–CD40 ligand signaling in atherosclerosis

Mach, F., Schönbeck, U., Sukhova, G. K., Bourcier, T., Bonnefoy, J., Pober, J. S., & Libby, P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.1931 · Cited by 730

CD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanism

André, P., Prasad, K. S. S., Denis, C. V., He, M.-S., Papalia, J. M., Hynes, R. O., Phillips, D. R., & Wagner, D. D. (2002) · Nature Medicine · doi:10.1038/nm0302-247 · Cited by 725

Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand

Kawai, T., Andrews, D. M., Colvin, R. B., Sachs, D. H., & Cosimi, A. B. (2000) · Nature Medicine · doi:10.1038/72162 · Cited by 693

Local Administration of Soluble CD40:Fc to the Salivary Glands of Non-Obese Diabetic Mice Does Not Ameliorate Autoimmune Inflammation

Roescher, N., Vosters, J. L., Lai, Z., Uede, T., Tak, P. P., & Chiorini, J. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051375 · Cited by 15

Abatacept in the treatment of lupus

Hoi, A. Y.-B., & Littlejohn, G. O. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.713934 · Cited by 15

Beyond calcineurin inhibitors

Safa, K., Riella, L. V., & Chandraker, A. K. (2013) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e328365b3e6 · Cited by 15

New therapeutic avenues in SLE

Bakshi, J., Ismajli, M., & Rahman, A. (2015) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2016.02.007 · Cited by 15

New approaches to prevent transplant rejection: Co-stimulation blockers anti-CD40L and CTLA4Ig

Pree, I., & Wekerle, T. (2006) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2006.02.002 · Cited by 15

General Principles of Tumor Immunotherapy

Kaufman, H. L., & Wolchok, J. D. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6087-8 · Cited by 15

Clinical Flow Cytometry - Emerging Applications

Schmid, I. (2012) · InTech eBooks · doi:10.5772/2680 · Cited by 14

A systems approach to renal inflammation in SLE

Berthier, C. C., Kretzler, M., & Davidson, A. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.08.015 · Cited by 14

PHARMACOLOGY AND DRUG THERAPY

Laxer, R. M. (2005) · Elsevier eBooks · doi:10.1016/b978-1-4160-0246-8.50011-5 · Cited by 14

A CD40 targeting peptide prevents severe symptoms in experimental autoimmune encephalomyelitis

Vaitaitis, G. M., Yussman, M. G., & Wagner, D. H. (2019) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2019.03.013 · Cited by 13

Monoclonal antibody‐mediated immunosuppression enables long‐term survival of transplanted human neural stem cells in mouse brain

McGinley, L. M., Chen, K. S., Mason, S. N., Rigan, D. M., Kwentus, J. F., Hayes, J. M., Glass, E., Reynolds, E. L., Murphy, G. G., & Feldman, E. L. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1046 · Cited by 13

Cell-Based Therapy in Allergy

Baranyi, U., Gattringer, M., Valenta, R., & Wekerle, T. (2011) · Current topics in microbiology and immunology · doi:10.1007/82_2011_127 · Cited by 13

Physiopathologie du purpura thrombopénique immunologique

Audia, S., Lorcerie, B., Godeau, B., & Bonnotte, B. (2010) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2009.05.017 · Cited by 13

Recent Progress in Managing Graft-Versus-Host Disease and Viral Infections Following Allogeneic Stem Cell Transplantation

Sellar, R. S., & Peggs, K. S. (2012) · Future Oncology · doi:10.2217/fon.12.153 · Cited by 12

The identification of TNFR5 as a therapeutic target in diabetes

Turner, M. D. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1297426 · Cited by 11

Considering future qualification for regulatory science in the early development of microphysiological systems: a case study of microthrombosis in a Vessel-on-Chip

Weener, H. J., Middelkamp, H. H. T., & Van der Meer, A. D. (2024) · Frontiers in Toxicology · doi:10.3389/ftox.2024.1513002 · Cited by 10

Hurdles to the Induction of Tolerogenic Mixed Chimerism

Pilat, N., Klaus, C., Schwaiger, E., & Wekerle, T. (2009) · Transplantation · doi:10.1097/tp.0b013e3181a2b9cc · Cited by 10

Inhibiting CD40 Ligand in Multiple Sclerosis: A Review of Emerging Therapeutic Potential

Vermersch, P., Wagner, D. H., Mars, L. T., Noelle, R. J., & Giovannoni, G. (2024) · Current Treatment Options in Neurology · doi:10.1007/s11940-024-00818-2 · Cited by 9

Implications of CD154 and Its Receptors in the Pathogenesis and Treatment of Systemic Lupus Erythematosus

Allard, C. C., Salti, S., Mourad, W. M., & Hassan, G. S. (2024) · Cells · doi:10.3390/cells13191621 · Cited by 9

Dendritic cell-targeted CD40 DNA vaccine suppresses Th17 and ameliorates progression of experimental autoimmune glomerulonephritis

Li, Q., Cao, Q., Wang, C., Nguyen, H. P., Wang, X. M., Zheng, G., Wang, Y. M., Hu, S., Alexander, S. I., Harris, D. C. H., et al. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.5a0818-333r · Cited by 9

CD40 and CD72 expression and prognostic values among children with systemic lupus erythematosus: a case–control study

Asmiyou, A., Bakr, A., Shahin, D. A., & Wahba, Y. (2020) · Lupus · doi:10.1177/0961203320941931 · Cited by 9

An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade

Kälble, F., Schaier, M., Schäfer, S., Süsal, C., Zeier, M., Sommerer, C., & Morath, C. P. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1323876 · Cited by 8

The Efficacy of CD40 Ligand Blockade in Discordant Pig-to-Rat Islet Xenotransplantation Is Correlated with an Immunosuppressive Effect of Immunoglobulin

Wennberg, L. M., Goto, M., Maeda, A., Song, Z., Benjamin, C. D., GROTH, C. G., & Korsgren, O. (2005) · Transplantation · doi:10.1097/01.tp.0000147317.96481.db · Cited by 7

Potential Pathways Associated With Exaggerated T Follicular Helper Response in Human Autoimmune Diseases

Horiuchi, S., & Ueno, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01630 · Cited by 7

Blocking Costimulatory Pathways: Prospects for Inducing Transplantation Tolerance

Verbinnen, B., Gool, S. W. V., & Ceuppens, J. L. (2010) · Immunotherapy · doi:10.2217/imt.10.31 · Cited by 7

Bone marrow transplantation as a strategy for tolerance induction in the clinic

Pree, I. (2009) · Frontiers in bioscience · doi:10.2741/3267 · Cited by 7

Multiple-Sklerose-Update zur Pathophysiologie und neuen immuntherapeutischen Ansätzen

Kleinschnitz, C., Meuth, S. G., Kieseier, B. C., & Wiendl, H. (2007) · Der Nervenarzt · doi:10.1007/s00115-007-2261-9 · Cited by 6

Autoantibodies in neuromuscular autoimmune disorders

Lang, B., & Willcox, N. (2006) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2.2.293 · Cited by 5

Papel de los fármacos biológicos en el tratamiento de las enfermedades autoinmunitarias

Espinosa, G., & Cervera, R. (2007) · Medicina Clínica · doi:10.1157/13100566 · Cited by 5

Tolerance--Is It Worth It?Preprint

Finger, E. B., Strom, T. B., & Matas, A. J. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015594 · Cited by 5

Novel and Emerging Treatments to Target Pathophysiological Mechanisms in Various Phenotypes of Multiple Sclerosis

Bsteh, G., Bianco, A. D., Zrzavy, T., & Berger, T. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001073 · Cited by 4

Modulating CD40 and integrin signaling in the proinflammatory nexus using a 15-amino-acid peptide, KGYY15

Vaitaitis, G. M., & Wagner, D. H. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104625 · Cited by 4

Targeting Cells Causing Split Tolerance Allows Fully Allogeneic Islet Survival With Minimal Conditioning in NOD Mixed Chimeras

Al‐Adra, D. P., Pawlick, R. L., Shapiro, A. M. J., & Anderson, C. C. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04260.x · Cited by 4

What can we learn from systemic lupus erythematosus pathophysiology to improve current therapy?

Vilas‐Boas, A., Bakshi, J., & Isenberg, D. A. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.1078237 · Cited by 4

Lupus nephritis: a review of the current pharmacological treatments

Mercadal, L., & Deray, G. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.11.2263 · Cited by 4

Treat‐To‐Target: Emergence of Second‐Generation CD 40 L Inhibitors for Treatment of SLE —Identifying Beneficial Patient Candidates for CD 40 L Inhibitors in a Cross‐Sectional SLE Cohort

Pedersen, K., Hansen, A. G., Palarasah, Y., Troldborg, A., & Thiel, S. (2025) · Scandinavian Journal of Immunology · doi:10.1111/sji.70050 · Cited by 3

Blockade of adhesion molecule lymphocyte function–associated antigen-1 improves long-term heart allograft survival in mixed chimeras

Pilat, N., Sabler, P., Klaus, C., Mahr, B., Unger, L. W., Hock, K., Wiletel, M., Schwarz, C. C., Kristo, I., Regele, H. M., et al. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2018.03.016 · Cited by 3

Current use and development of monoclonal antibodies for the treatment of systemic lupus erythematosus: a review

Blagov, A. V., Orekhov, N. A., Churov, A. V., Starodubtseva, I. A., Beloyartsev, D. F., Kovyanova, T. I., Sukhorukov, V. N., & Orekhov, A. N. (2024) · Antibody Therapeutics · doi:10.1093/abt/tbae033 · Cited by 2

Biologic Agents in the Treatment of Systemic Lupus Erythematosus

Kyttaris, V. C. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-374994-9.10059-2 · Cited by 2

Toward minimal conditioning protocols for allogeneic chimerism in tolerance resistant recipients

Al‐Adra, D. P., & Anderson, C. C. (2012) · Chimerism · doi:10.4161/chim.23350 · Cited by 2

Methods for measurement of platelet function in the assessment of nonclinical drug safety and implications for translatability

Ledieu, D., & Côté, S. (2019) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2019.10.005 · Cited by 2

Progress toward islet transplantation tolerance

Markmann, J. F., & Rickert, C. G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814833-4.00058-7 · Cited by 2

Transplantation Immunobiology

Ingulli, E. G., Alexander, S. I., & Briscoe, D. M. (2009) · Springer eBooks · doi:10.1007/978-3-540-76341-3_74 · Cited by 2

Advances in the CD40-mediated Manipulation Strategies

Bandyopadhyay, S. (2023) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/3067 · Cited by 1

Clinical advances in immunotherapy for immune-mediated glomerular diseases

Tang, B., & Yang, X. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01218-7 · Cited by 1

Blockade of CD40–CD40 Ligand Interactions Attenuates Skin Fibrosis and Autoimmunity in the Tight-skin Mouse

Komura, K., Fujimoto, M., Hasegawa, M., & Sato, S. (2007) · Clinical Immunology · doi:10.1016/j.clim.2007.03.104 · Cited by 1

Theme Issue Article

Tratar, G. (2004) · Cited by 1

High-Dimensional Renal Profiling: Towards a Better Understanding of Renal Transplant Immune Suppression

Castro-Rojas, C. M., Alloway, R. R., Woodle, E. S., & Hildeman, D. A. (2019) · Current Transplantation Reports · doi:10.1007/s40472-019-0225-1 · Cited by 1

Transplantation Immunobiology

Sayegh, M. H., & Chandraker, A. K. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10070-3 · Cited by 1

Immunology of Pediatric Renal Transplantation

Ingulli, E. G., Alexander, S. I., & Briscoe, D. M. (2015) · Springer eBooks · doi:10.1007/978-3-662-43596-0_64 · Cited by 1

T Follicular Helper Cells as a Therapeutic Target for Autoimmune Diseases

Ueno, H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801577-3.00008-3 · Cited by 1

Biothérapies dans le lupus systémique : de nouvelles cibles

Lazaro, E., Scherlinger, M., Truchetet, M., Chiche, L., Schaeverbeke, T., Blanco, P., & Richez, C. (2016) · Revue du Rhumatisme · doi:10.1016/j.rhum.2016.06.002 · Cited by 1

Biologics in Sjogren’s Syndrome

Price, E. (2022) · Springer eBooks · doi:10.1007/978-981-16-7200-2_7 · Cited by 1

Mecanismos de modulação da via de sinalização CD40/CD40L.

de Souza, H. P. (2009) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2009.tde-25032009-094737 · Cited by 1

On the Road to Tolerance Induction in Composite Tissue Allotransplantation

Hardy, M. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-74682-1_7

Hodgkin Lymphoma and the Microenvironment

Cascio, M. J., & Natkunam, Y. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386456-7.04108-3

Future Pathways for Immune Manipulation

Webber, A. B., & Vincenti, F. G. (2014) · Wiley eBooks · doi:10.1002/9781118873434.ch18

B Cells in Health and Disease – Leveraging Flow Cytometry to Evaluate Disease Phenotype and the Impact of Treatment with Immunomodulatory Therapeutics

Cherie, L., Ferbas, J., & Barbara, A. (2012) · InTech eBooks · doi:10.5772/38288

Immunomodulatory Molecules of the Immune System

Saenger, Y. M., Jenq, R. R., & Perales, M. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6087-8_5

Therapeutic strategies for refractory systemic lupus erythematosus

Sidiropoulos, P. I., Bertsias, G. K., Kritikos, H. D., & Boumpas, D. T. (2004) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2004.11.011

T Cell Targeted Therapies in Lupus: Do They Make Sense?

Thanou, A., & Merrill, J. T. (2015) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-014-0008-x

Mecanismos de modulação da via de

Paulo, S. (2007)

Identification of novel mechanisms of glucolipotoxicity in type 2 diabetes

Bagnati, M. (2015)

The role of platelet-macrophage interactions in inflammation and wound healing

Scull, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/ct85-ea84

nola de Reumatología sobre el uso de terapias biológicas en el lupus eritematoso sistémico

Alén, J. C., Silva-Fernández, L., Angulo, E. U., Pego‐Reigosa, J. M., Olivé, A., Martı́nez, C., Marenco, J. L., Lόpez-Longo, J., Gómez-Reino, J. J., & Cuadrado, M. J. (2016)

Future therapies in lung transplantation

Lendermon, E. A., & McDyer, J. F. (2015) · CRC Press eBooks · doi:10.1201/b19234-38

Defining the barrier of split tolerance in allogeneic mixed chimerism

Al‐Adra, D. P. (2012) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3wf0d

Novel Immunosuppressive Drugs

Wojciechowski, D., & Vincenti, F. G. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-0268-8.00095-6

Application of Minimal Anticipated Biological Effect Level ( MABEL ) in Human Starting Dose Selection for Immunomodulatory Protein Therapeutics – Principles and Case Studies

Wang, H., Yang, Z., & Shi, R. (2019) · Wiley eBooks · doi:10.1002/9781119289234.ch4

Experimental therapies in primary Sjögren’s syndrome

Fisher, B. A. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780198806684.003.0029

Immunology and Immunotherapy of Graft-Versus-Host Disease

Haase, D., & Afshari, F. (2020) · Springer eBooks · doi:10.1007/978-3-030-57949-4_22

Immunology of Pediatric Renal Transplantation

Ingulli, E. G., Alexander, S. I., & Briscoe, D. M. (2015) · Springer eBooks · doi:10.1007/978-3-642-27843-3_64-1

Future therapies in lung transplantation

Lendermon, E. A., & McDyer, J. F. (2015) · CRC Press eBooks · doi:10.1201/b19234-43

Organ-specific autoimmune disorders

Chatterjee, S., Yadav, M., Sharma, H., Jha, B., Neelam, D. K., Thakre, V., Pathak, H., Devki, & Kumar, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-18776-6.00003-7

Lowering CD40L expression in murine lupus results in an increase in disease indicators in female but not male B6 mice

Maio, D. P. D., Tetteh, S., Ayers, C., Martin, A. S., Brown, M., & Covey, L. R. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag205

Immunology and Immunotherapy of Graft-Versus-Host Disease

Haase, D. (2015) · Springer eBooks · doi:10.1007/978-3-662-46410-6_24

Evaluation in vivo de protéines immunorégulatrices dérivées de CTLA-4 et de PD-L1 pour leur capacité à inhiber les réponses immunitaires dans le contexte de la thérapie génique musculaire par AAV

Dupaty, L. (2018) · theses.fr (ABES) · doi:10.70675/2a43547aze940z43ffz9330z38dd4997e21b

Platelets in systemic lupus erythematosus: from hemostatic allies to pathogenic drivers

Wu, Y., Yang, Z., Huang, S., Bao, J., Fan, Y., & Xie, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1778274

Germinal Centers Function as Macromolecular Sanctuaries that Protect Follicular T Cells from Immunotoxin-Mediated DepletionPreprint

Kim, S., Shukla, R. K., Golconda, S., Yu, H., Reneau, J. C., Liyanage, N. P. M., Hanel, W. G., & Kim, S. (2026) · Research Square · doi:10.21203/rs.3.rs-11628345/v1

Review of Novel Immunotherapeutic Strategies for MS

Wiendl, H., & Hohlfeld, R. (2007) · Springer eBooks · doi:10.1007/978-0-387-36003-4_14

Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism

Nakamura, M., Tanaka, Y., Satoh, T., Kawai, M., Hirakata, M., Kaburaki, J., Kawakami, Y., Ikeda, Y., & Kuwana, M. (2005) · Rheumatology · doi:10.1093/rheumatology/kei118 · Cited by 36

Phoenix from the flames: Rediscovering the role of the CD40–CD40L pathway in systemic lupus erythematosus and lupus nephritis

Ramanujam, M., Steffgen, J., Visvanathan, S., Mohan, C., Fine, J. S., & Putterman, C. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102668 · Cited by 87

The effect of anti‐CD40 ligand antibody on B cells in human systemic lupus erythematosus

Huang, W., Sinha, J., Newman, J., Reddy, B., Budhai, L., Furie, R. A., Vaishnaw, A. K., & Davidson, A. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10273 · Cited by 165

Elevated levels of soluble CD40 ligand are associated with antiphospholipid antibodies in patients with systemic lupus erythematosus.

Kim, K., Baek, I., Yoon, C., Kim, W., & Cho, C. (2017) · PubMed · Cited by 17

Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response

Early, G. S., Zhao, W., & Burns, C. M. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.7.3159 · Cited by 215